breast cancer: Gland Pharma gets USFDA nod for generic breast cancer drug : vimarsana.com

Gland Pharma has received approval from the USFDA to market a generic medication for breast cancer treatment, Eribulin Mesylate Injection. It's expected to be the first generic approval in the market, with sales of around USD 92 million in the US.

Related Keywords

, Drug Administration , Orbicular Pharmaceutical Technologies Pvt Ltd , Gland Pharma , Eribulin Mesylate Injection , Orbicular Pharmaceutical Technologies Pvt , Breast Cancer , Usfda , Us Food And Drug Administration , Iqvia ,